Last reviewed · How we verify

Alendronate (Fosamax) — Competitive Intelligence Brief

Alendronate (Fosamax) (Alendronate (Fosamax)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Bone metabolism / Rheumatology.

marketed Bisphosphonate Farnesyl pyrophosphate synthase (FPPS); hydroxyapatite binding Bone metabolism / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Alendronate (Fosamax) (Alendronate (Fosamax)) — Medical University of South Carolina. Alendronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite on bone surfaces and blocking the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Alendronate (Fosamax) TARGET Alendronate (Fosamax) Medical University of South Carolina marketed Bisphosphonate Farnesyl pyrophosphate synthase (FPPS); hydroxyapatite binding
Boniva IBANDRONIC ACID Hoffmann La Roche marketed Bisphosphonate Farnesyl pyrophosphate synthase 2003-01-01
Skelid TILUDRONIC ACID marketed Bisphosphonate 72 kDa type IV collagenase 1997-01-01
Aredia PAMIDRONIC ACID marketed Bisphosphonate Farnesyl pyrophosphate synthase 1991-01-01
Didronel ETIDRONIC ACID Procter And Gamble marketed Bisphosphonate 1977-01-01
Alendronate (ALN) Alendronate (ALN) Chinese University of Hong Kong marketed Bisphosphonate Farnesyl pyrophosphate synthase (FPPS); hydroxyapatite
Ibandronate IV Ibandronate IV National Taiwan University Hospital marketed Bisphosphonate Farnesyl pyrophosphate synthase; hydroxyapatite in bone

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

  1. · 2 drugs in this class
  2. Amgen · 2 drugs in this class
  3. National Taiwan University Hospital · 2 drugs in this class
  4. Sanofi · 2 drugs in this class
  5. Ludwig-Maximilians - University of Munich · 2 drugs in this class
  6. Chinese University of Hong Kong · 1 drug in this class
  7. Chinese Society of Lung Cancer · 1 drug in this class
  8. Aarhus University Hospital · 1 drug in this class
  9. Eisai Inc. · 1 drug in this class
  10. Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alendronate (Fosamax) — Competitive Intelligence Brief. https://druglandscape.com/ci/alendronate-fosamax. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: